Alloimmunization Against Human Platelet Antigen 2 (Hpa2) In A Series Of Multi-Transfused Beta-Thalassemia Patients

In our study we investigated the presence of anti-human platelet antigen (HPA) alloantibodies in a series of 10 beta-thalassemia major patients submitted for more than 10 years to periodic blood transfusions (every 2-3 weeks). We found that 2! out of the 10 patients developed anti-HPA2a+HPA1b and anti-HPA2b antibodies. Our results highlight that HPA alloimmunization in multitransfused patients is a real possibility.